CN105073767B - 稳定的s‑腺苷‑l‑蛋氨酸的吲哚‑3‑丙酸盐 - Google Patents

稳定的s‑腺苷‑l‑蛋氨酸的吲哚‑3‑丙酸盐 Download PDF

Info

Publication number
CN105073767B
CN105073767B CN201480005105.4A CN201480005105A CN105073767B CN 105073767 B CN105073767 B CN 105073767B CN 201480005105 A CN201480005105 A CN 201480005105A CN 105073767 B CN105073767 B CN 105073767B
Authority
CN
China
Prior art keywords
methionine
adenosyl
indole
same
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480005105.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105073767A (zh
Inventor
罗兰·F·赫伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebert Sam E LLC
Original Assignee
Hebert Sam E LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebert Sam E LLC filed Critical Hebert Sam E LLC
Publication of CN105073767A publication Critical patent/CN105073767A/zh
Application granted granted Critical
Publication of CN105073767B publication Critical patent/CN105073767B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480005105.4A 2013-01-16 2014-01-16 稳定的s‑腺苷‑l‑蛋氨酸的吲哚‑3‑丙酸盐 Active CN105073767B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361753300P 2013-01-16 2013-01-16
US61/753,300 2013-01-16
US201361792467P 2013-03-15 2013-03-15
US61/792,467 2013-03-15
PCT/US2014/011935 WO2014113609A1 (en) 2013-01-16 2014-01-16 Stable indole-3-propionate salts of s-adenosyl-l-methionine

Publications (2)

Publication Number Publication Date
CN105073767A CN105073767A (zh) 2015-11-18
CN105073767B true CN105073767B (zh) 2018-01-02

Family

ID=51210072

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480005105.4A Active CN105073767B (zh) 2013-01-16 2014-01-16 稳定的s‑腺苷‑l‑蛋氨酸的吲哚‑3‑丙酸盐

Country Status (7)

Country Link
US (1) US9534010B2 (enExample)
EP (1) EP2945959B1 (enExample)
JP (1) JP6479681B2 (enExample)
KR (1) KR102186066B1 (enExample)
CN (1) CN105073767B (enExample)
ES (1) ES2824807T3 (enExample)
WO (1) WO2014113609A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700074957A1 (it) 2017-07-04 2019-01-04 Gnosis Spa Sale di (ss)-adenosil metionina con inositolo esafosfato e procedimento per ottenerlo
US11324774B2 (en) * 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
JP2021046375A (ja) * 2019-09-19 2021-03-25 ポッカサッポロフード＆ビバレッジ株式会社 β３アドレナリン受容体活性化剤
CN117883439A (zh) * 2024-01-18 2024-04-16 中国人民解放军陆军军医大学第一附属医院 吲哚-3-丙酸在制备抑制破骨细胞分化药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028183A (en) * 1973-06-27 1977-06-07 Bioresearch Limited Process of preparing double salts of S-adenosyl-L-methionine
US5102791A (en) * 1984-05-16 1992-04-07 Bioresearch S.P.A. Stable sulpho-adendoyl-l-methionine (same) salts, particlarly suitable for parenteral use
US20030032796A1 (en) * 2001-06-07 2003-02-13 Deshpande Pandurang Balwant New stable salts of S-adenosyl-L-methionine (SAMe) and the process for their preparation
WO2007004244A1 (en) * 2005-06-30 2007-01-11 Maria De Luca Salts or complexes of methyl donors with phytic acid or its derivatives and method for the synthesis thereof
US20100004191A1 (en) * 2008-07-01 2010-01-07 Rolland F Hebert Compositions of S-adenosyl-L-methionine.
CN101730704A (zh) * 2007-07-10 2010-06-09 灵知股份公司 S-腺苷甲硫氨酸的稳定的盐及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969353A (en) 1957-02-06 1961-01-24 Merck & Co Inc Process for the preparation of "active methionine" and products obtained thereby
DE1803978C2 (de) 1968-10-18 1985-05-02 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Gewinnung von S-Adenosyl-l-methionin und S-Adenosyl-l-ethionin
IE37913B1 (en) 1972-08-02 1977-11-09 Bioresearch Sas Salt of s-adenosyl-l-methionine
IE39517B1 (en) 1973-06-27 1978-10-25 Bioresearch Sas Double salts of s-adenosyl-l-methhionine
AR221676A1 (es) 1974-07-12 1981-03-13 Bioresearch Sas Procedimiento para la preparacion de sales estables sulfonicas y/o sulfuricas de la s-adenosil-l-metionina,particularmente utiles como donadores especificos de metilo para las reacciones bioquimicas de transferencia del grupo ch3;asi como tambien las reacciones fundamentales en el metabolismo lipilico,protilico y glucidico
US4109079A (en) 1975-10-16 1978-08-22 Yamasa Shoyu Kabushiki Kaisha Stabilized s-adenosyl-l-methionine preparations
GB2001976B (en) 1977-08-03 1982-03-10 Yamasa Shoyu Kk S-adenosyl-l-methionine compositions and production thereof
GB2064523B (en) 1979-12-04 1983-06-29 Kanegafuchi Chemical Ind Stable composition of s-adenosyl-l-methionine
IT1137640B (it) 1981-08-24 1986-09-10 Bioresearch Srl Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
IT1137892B (it) 1981-08-24 1986-09-10 Bioresearch Srl Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
IT1139974B (it) 1981-09-11 1986-09-24 Bioresearch Srl Derivati della s-adenosilmetionina,processo per la preparazione e composizioni terapeutiche che li contengono come principio attivo
IT1169774B (it) 1983-08-24 1987-06-03 Bioresearch Spa Composizioni terapeutiche iniettabili contenenti sali stabili della s-adenosil-l-metionina
IT1173992B (it) 1984-05-16 1987-06-24 Bioresearch Spa Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale
IT1200589B (it) 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
AU2538588A (en) 1987-10-09 1989-05-02 Mario De Rosa Lipophilic salts of s-adenosyl-l-methionine (sam) with acylated taurine derivatives
JPH02290896A (ja) 1989-04-28 1990-11-30 Fuji Kagaku Kogyo Kk 新規なｓ―アデノシルメチオニン誘導体
DE19632823C1 (de) 1996-08-14 1997-11-20 Symbio Herborn Group Gmbh & Co Komplexe zwischen S-(+)-Adenosylmethionin und 3'-Azido-2',3'-didesoxynucleosid als potente Inhibitoren der HIV-Replikation
IT1318535B1 (it) 2000-05-25 2003-08-27 Chementecno Srl Processo per la preparazione di sali farmaceuticamente accettabili di(ss,rs)-s-adenosil-l-metionina.
KR20020088498A (ko) 2001-05-17 2002-11-29 (주)미토콘 에스-아데노실메티오닌을 유효성분으로 함유하는 인슐린저항증 개선용 조성물
US6881837B2 (en) 2001-06-07 2005-04-19 Orchid Chemicals & Pharmaceuticals Ltd. Chemical synthesis of S-adenosyl-L-methionine with enrichment of (S,S)-isomer
US20040029830A1 (en) * 2002-08-06 2004-02-12 Hebert Rolland F. Water-soluble indole-3-propionic acid
US20050272687A1 (en) * 2004-06-08 2005-12-08 Hebert Rolland F Stable S-adenosyl-l-methionine
US20060127506A1 (en) * 2004-12-10 2006-06-15 Hebert Rolland F Compositions of S-adenosyl-L-methionine
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028183A (en) * 1973-06-27 1977-06-07 Bioresearch Limited Process of preparing double salts of S-adenosyl-L-methionine
US5102791A (en) * 1984-05-16 1992-04-07 Bioresearch S.P.A. Stable sulpho-adendoyl-l-methionine (same) salts, particlarly suitable for parenteral use
US20030032796A1 (en) * 2001-06-07 2003-02-13 Deshpande Pandurang Balwant New stable salts of S-adenosyl-L-methionine (SAMe) and the process for their preparation
WO2007004244A1 (en) * 2005-06-30 2007-01-11 Maria De Luca Salts or complexes of methyl donors with phytic acid or its derivatives and method for the synthesis thereof
CN101730704A (zh) * 2007-07-10 2010-06-09 灵知股份公司 S-腺苷甲硫氨酸的稳定的盐及其制备方法
US20100004191A1 (en) * 2008-07-01 2010-01-07 Rolland F Hebert Compositions of S-adenosyl-L-methionine.

Also Published As

Publication number Publication date
JP2016505009A (ja) 2016-02-18
JP6479681B2 (ja) 2019-03-06
ES2824807T3 (es) 2021-05-13
KR102186066B1 (ko) 2020-12-04
US20150344517A1 (en) 2015-12-03
KR20150115804A (ko) 2015-10-14
WO2014113609A1 (en) 2014-07-24
CN105073767A (zh) 2015-11-18
US9534010B2 (en) 2017-01-03
EP2945959B1 (en) 2020-05-13
EP2945959A1 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
US9745335B2 (en) N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application
CN105073767B (zh) 稳定的s‑腺苷‑l‑蛋氨酸的吲哚‑3‑丙酸盐
EP4197538A1 (en) Egfr inhibitor
CN114746095B (zh) Hck作为myd88突变疾病的治疗靶点
US20230310640A1 (en) Pyrrolobenzodiazepine derivative and ligand-linker conjugate thereof
CN115850291A (zh) 喜树碱衍生物及其用途
CN108472300A (zh) 氰基噻吩并三唑并二氮杂环庚三烯及其用途
KR20240055788A (ko) 신규한 ras 억제제
US20250057960A1 (en) Oligosaccharide complexes and uses
CN109651377B (zh) 一种治疗癌症的化合物及其用途
JP2018509424A (ja) 疾患を処置するためのコンジュゲート
US8633168B2 (en) Inhibitors of S-adenosyl-L-methionine decarboxylase
US20230242558A1 (en) Nicotinate and nicotinamide riboside-based compounds and derivatives thereof
Morana et al. Synthesis and characterisation of a new class of stable S-adenosyl-l-methionine salts
US20050272687A1 (en) Stable S-adenosyl-l-methionine
US20240247024A1 (en) Inhibitors of nicotinamide n-methyl transferase (nnmt)
US10899787B2 (en) Cytarabine prodrug nucleoside cyclic phosphate compound based on liverspecific delivery and use
EP2852601A1 (en) Semisynthetic derivatives of nystatin a1
US20120040923A1 (en) Stable s-adenosyl-l-methionine
EP4471025A1 (en) Ezh1/2 inhibitor, preparation thereof, and use thereof in anti-tumor therapy
US11008361B2 (en) Liver-specific delivery-based anti-hepatitis C prodrug nucleoside cyclo-phosphate compound and uses thereof
US20070135436A1 (en) Chemical compounds
WO2024184316A1 (en) Bifunctional protein targeting chimeras (protacs) comprising arylidene-indolinone scaffold as dcaf11 ligand and use thereof
CN120114464A (zh) 一种磷类化合物及其在抗肿瘤方面中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant